alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 126–150 of 154 studies with an author at Wake Forest University (US) (page 6 of 7) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 154 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Cerebral small vessel disease and effects of intensive versus standard blood pressure treatment on cardiovascular outcomes and adverse events

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Hypertension 2025-06-27

The mean age of the participants was 68 ± 9 years and 39% were female. 5 key findings →

Design: post-hoc analysis Participants: 759 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Review: cerebral microvascular pathology in ageing and neurodegeneration

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Neuropathology and applied neurobiology 2011-02-01

This review of age-related brain microvascular pathologies focuses on topics studied by this laboratory, including anatomy of the blood supply, tortuous vessels, venous collagenosis, capillary remnants, vascular density and microembolic brain injury. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dementia in a resource‐constrained sub‐Saharan African setting: A comprehensive retrospective analysis of prevalence, risk factors, and management at the only neuropsychiatric facility in Northeastern Nigeria

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s & Dementia 2025-03-01

Of the 1216 cases reported, Alzheimer's disease (60.5%) was the most common subtype, followed by vascular dementia (24.5%). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Estimation of the value-based price of a blood test for Alzheimer's disease pathology in primary and specialty care in the U.S

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Prevention of Alzheimer's Disease 2025-06-09

The results project substantial cost savings from implementing a blood test for AD pathology within the diagnostic pathway based on modeling results, which future research should confirm with actual data. 4 key findings →

Design: modelling Evidence: preliminary

Full summary, score breakdown and related studies → Original source Free full text

Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies

✓ Peer-reviewed alzhub usefulness score 44 out of 100. American heart journal 2012-07-03

In the 3 studies combined, the data indicated that rofecoxib more than tripled the risk of confirmed CVT death (risk ratio = 3.57 [1.48-9.72], P = .004). 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Polygenic Risk Scores for Incident Dementia in the Multi‐Ethnic Study of Atherosclerosis

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Genetic Epidemiology 2026-06-23

We found comparable associations between dementia and PRS when comparing a C+T method with only 15 SNPs and PRS derived from Bayesian models that include > 800,000 SNPs (HR 5e‐08 = 1.18, 95% CI: 1.08–1.28; HR CSx = 1.17, 95% CI: 1.07−1.27). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Risk of a Dementia Diagnosis in Community-Dwelling Older Adults With Normal MMSE Scores in the United States

✓ Peer-reviewed alzhub usefulness score 44 out of 100. American Journal of Medicine Open 2026-02-25

• Lower MMSE scores—even by a single point—were independently associated with a significantly higher risk of developing ADRD. • Individuals with MMSE scores between 27 and 30 should not be viewed as a uniform group. • Further studies are needed to find ways to prevent ADRD in people who are at risk but do not yet show symptoms. 5 key findings →

Participants: 1,228 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Normative data for 8 neuropsychological tests in older blacks and whites from the atherosclerosis risk in communities (ARIC) study

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer disease and associated disorders 2015-01-01

Accurate assessment of cognitive impairment requires comparison of cognitive performance in individuals to performance in a comparable healthy normative population. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

An Enteric Bacterial Infection Triggers Neuroinflammation and Neurobehavioral Impairment in 3xTg-AD Transgenic Mice

✓ Peer-reviewed alzhub usefulness score 43 out of 100. The Journal of infectious diseases 2024-09-01

Klebsiella pneumoniae is infamous for hospital-acquired infections and sepsis, which have also been linked to Alzheimer disease (AD)-related neuroinflammatory and neurodegenerative impairment. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effects of structural and social determinants of health and comorbidities on ethno‐racial differences in ATN plasma biomarkers of Alzheimer’s disease: A HABS‐HD study

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia 2023-12-01

Using a large and diverse community‐based cohort, we demonstrate that ethno‐racial differences in AD‐specific plasma biomarkers are, in part, due to modifiable health and comorbidity factors. 2 key findings →

Participants: 931 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies

✓ Peer-reviewed alzhub usefulness score 42 out of 100. American Journal of Neuroradiology 2025-07-10

Alzheimer disease (AD) is the leading cause of dementia, with an estimated 6.9 million Americans aged 65 and older living with Alzheimer dementia today, with this number projected to grow to 13.8 million by 2060. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Heterogeneity in the Genetic Architecture of Alzheimer disease (AD) across Ancestry Groups

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia 2025-12-01

Overall SNP‐based heritability estimates using this restricted set of variants varied: AA ( h 2 = 0.13, SE=0.05), NHW ( h 2 = 0.14, SE=0.01), AsA ( h 2 = 0.29, SE=0.09) and HL ( h 2 = 0.48, SE=0.17). 2 key findings →

Participants: 6,343 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Screening for the Spectrum of Cognitive Impairment in Primary Care: Development of a Machine Learning Informed, Workflow‐Friendly Care Model

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2024-12-01

In the testing cohort, the super learner obtained a concordance statistic (95% confidence interval) of 0.822 (0.810, 0.835), higher than any of the individual ML models (Figure 1), and its predicted risk aligned with observed risk in calibration slope plots (Figure 2). 2 key findings →

Participants: 75 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Impact of race/ethnicity and area deprivation index on Alzheimer’s disease and related disorders biomarkers in the POINTER Cohort

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2024-12-01

The analyses of the community‐based U.S. POINTER indicate that AA/B individuals present differences in AD and related dementia biomarker values. nHW had higher fully adjusted cognitive scores. 5 key findings →

Participants: 644 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Novel early‐onset Alzheimer‐associated genes influence risk through dysregulation of glutamate, immune activation, and intracell signaling pathways

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2025-12-01

Alzheimer Disease (AD) is a highly polygenic dementia that presents with relatively earlier onset (≤65yo; EOAD) in about 5% of cases. 2 key findings →

Participants: 15 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

MIND diet moderates the associations between cerebrovascular and neurodegenerative disease burden and cognition

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Frontiers in Nutrition 2026-05-13

The MIND diet may buffer the cognitive consequences of cerebrovascular pathology and cortical atrophy in older adults at elevated dementia risk and promote cognitive resilience over general healthy eating guidelines. 2 key findings →

Design: post-hoc analysis Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impact of neighborhood disadvantage on cardiometabolic health and cognition in a community‐dwelling cohort

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2024-10-01

ADI was positively associated with blood pressure and cardiometabolic index (CMI), and negatively associated with global and Preclinical Alzheimer's Cognitive Composite (PACC5) scores, in cognitively unimpaired (CU) individuals. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed